Research Progress of Radiolabeled Asn-Gly-Arg (NGR) Peptides for Imaging and Therapy
- PMID: 32862776
- PMCID: PMC7466889
- DOI: 10.1177/1536012120934957
Research Progress of Radiolabeled Asn-Gly-Arg (NGR) Peptides for Imaging and Therapy
Abstract
Asn-Gly-Arg (NGR) motifs have vasculature-homing properties via interactions with the aminopeptidase N (CD13) expressed on tumor neovasculature. Numerous NGR peptides with different molecular scaffolds have been exploited for targeted delivery of different compounds for imaging and therapy. When conjugated with NGR, complexes recognize the CD13 receptor expressed on the tumor vasculature, which improves the specificity to tumor and avoids systematic toxic reactions. Both preclinical and clinical studies performed with these products suggest that NGR-mediated vascular targeting is an effective strategy for delivering bioactive amounts of cytokines to tumor endothelial cells. For molecular imaging, radiolabeled peptides have been the most successful approach and have been translated into clinic. This review describes current data on radiolabeled tumor vasculature-homing NGR peptides for imaging and therapy.
Keywords: NGR; imaging; radiolabeled; therapy; tumor.
Conflict of interest statement
Figures



Similar articles
-
Development of NGR-based anti-cancer agents for targeted therapeutics and imaging.Anticancer Agents Med Chem. 2012 Jan;12(1):76-86. doi: 10.2174/187152012798764714. Anticancer Agents Med Chem. 2012. PMID: 22023047 Review.
-
The neovasculature homing motif NGR: more than meets the eye.Blood. 2008 Oct 1;112(7):2628-35. doi: 10.1182/blood-2008-04-150862. Epub 2008 Jun 23. Blood. 2008. PMID: 18574027 Free PMC article. Review.
-
Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif.Mol Immunol. 2006 Apr;43(10):1509-18. doi: 10.1016/j.molimm.2005.10.009. Epub 2005 Dec 7. Mol Immunol. 2006. PMID: 16337683
-
Synthesis and evaluation of 64Cu-labeled monomeric and dimeric NGR peptides for MicroPET imaging of CD13 receptor expression.Mol Pharm. 2013 Jan 7;10(1):417-27. doi: 10.1021/mp3005676. Epub 2012 Dec 13. Mol Pharm. 2013. PMID: 23190134
-
NGR-based strategies for targeting delivery of chemotherapeutics to tumor vasculature.Anticancer Agents Med Chem. 2012 Mar;12(3):239-46. doi: 10.2174/187152012800228751. Anticancer Agents Med Chem. 2012. PMID: 22263803 Review.
Cited by
-
Scandium-44: Diagnostic Feasibility in Tumor-Related Angiogenesis.Int J Mol Sci. 2023 Apr 17;24(8):7400. doi: 10.3390/ijms24087400. Int J Mol Sci. 2023. PMID: 37108559 Free PMC article. Review.
-
CD13-Mediated Pegylated Carboxymethyl Chitosan-Capped Mesoporous Silica Nanoparticles for Enhancing the Therapeutic Efficacy of Hepatocellular Carcinoma.Pharmaceutics. 2023 Jan 28;15(2):426. doi: 10.3390/pharmaceutics15020426. Pharmaceutics. 2023. PMID: 36839748 Free PMC article.
-
Advances and prospects of cell-penetrating peptides in tumor immunotherapy.Sci Rep. 2025 Jan 27;15(1):3392. doi: 10.1038/s41598-025-86130-8. Sci Rep. 2025. PMID: 39870681 Free PMC article. Review.
-
Radionuclide imaging and therapy directed towards the tumor microenvironment: a multi-cancer approach for personalized medicine.Eur J Nucl Med Mol Imaging. 2022 Nov;49(13):4616-4641. doi: 10.1007/s00259-022-05870-1. Epub 2022 Jul 5. Eur J Nucl Med Mol Imaging. 2022. PMID: 35788730 Free PMC article. Review.
-
Peptides for diagnosis and treatment of ovarian cancer.Front Oncol. 2023 May 5;13:1135523. doi: 10.3389/fonc.2023.1135523. eCollection 2023. Front Oncol. 2023. PMID: 37213272 Free PMC article. Review.
References
-
- Angelo C, Curnis F. Tumor vasculature targeting through NGR peptide-based drug delivery systems. Curr Pharm Biotechnol. 2011;12(8):1128–1134. - PubMed
-
- Flavio C, Anna G, Angelina S, Cattaneo A, Magni F, Corti A. Targeted delivery of IFN; to tumor vessels uncouples antitumor from counterregulatory mechanisms. Cancer Res. 2005;65(7):2906–2913. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous